Who owns CBMG - CELLULAR BIOMEDICINE GROUP I - COM NEW based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

CELLULAR BIOMEDICINE GROUP I - COM NEW (CBMG) Institutional Ownership

Q: What is CUSIP 15117P102?

CUSIP 15117P102 is the security identifier used in SEC filing datasets for CBMG - CELLULAR BIOMEDICINE GROUP I - COM NEW.

CUSIP: 15117P102

13F Institutional Holders and Ownership History from Q3 2014 to Q2 2021

Type / Class: Equity / COM NEW
Symbol: CBMG

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 15117P102?
CUSIP 15117P102 identifies CBMG - CELLULAR BIOMEDICINE GROUP I - COM NEW in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 15117P102:

Q2 2021 (0 holders) Q1 2021 (0 holders) Q4 2020 (64 holders) Q3 2020 (69 holders) Q2 2020 (42 holders) Q1 2020 (40 holders) Q4 2019 (41 holders) Q3 2019 (39 holders) Q2 2019 (39 holders) Q1 2019 (40 holders)

Institutional Holders of CELLULAR BIOMEDICINE GROUP I - COM NEW (CBMG) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2021 Q2	0	$0	-$116,000	$0	$0		0
2021 Q1	0	$0	-$81,928,218	$0			0
2020 Q4	4,466,637	$82,091,476	+$3,461,810	$1,629,000	$53,000	$18.38	64
2020 Q3	4,279,391	$78,484,295	+$15,168,259	$1,172,000	$492,000	$18.34	69
2020 Q2	3,488,171	$52,210,156	-$12,299,633		$0	$14.97	42
2020 Q1	4,257,982	$67,344,065	-$2,568,233		$201,000	$15.82	40
2019 Q4	4,418,018	$71,744,104	+$2,819,803		$164,000	$16.24	41
2019 Q3	4,244,678	$63,068,798	+$4,638,419			$14.86	39
2019 Q2	3,920,041	$64,761,530	+$8,510,012			$16.53	39
2019 Q1	3,435,453	$59,425,697	+$30,656,266			$17.30	40
2018 Q4	1,660,936	$29,326,496	+$729,452	$0		$17.66	35
2018 Q3	1,619,407	$29,390,912	+$3,751,127	$303,000		$18.15	38
2018 Q2	1,412,247	$27,608,756	+$14,092,548	$0		$19.55	34
2018 Q1	694,108	$12,179,089	+$4,271,334	$209,000		$17.55	23
2017 Q4	453,738	$5,125,214	-$1,039,031			$11.29	15
2017 Q3	548,359	$5,838,796	-$2,459,842			$10.65	17
2017 Q2	812,775	$7,112,061	-$6,167,364			$8.75	23
2017 Q1	1,392,485	$16,429,767	+$6,352,367			$11.80	31
2016 Q4	1,459,521	$19,123,039	+$2,338,855		$0	$13.10	37
2016 Q3	1,278,313	$18,530,753	+$767,194		$180,000	$14.50	35
2016 Q2	1,228,431	$14,725,999	+$1,899,325			$11.99	33
2016 Q1	1,064,202	$19,846,492	+$1,116,064			$18.65	29
2015 Q4	1,001,411	$21,513,868	+$837,395			$21.48	32
2015 Q3	964,381	$16,321,173	+$948,610			$16.92	35
2015 Q2	806,551	$30,257,004	+$18,174,078			$37.51	45
2015 Q1	356,966	$11,230,000	+$10,430,802			$31.46	21
2014 Q4	32,386	$416,000	+$31,685			$12.77	5
2014 Q3	24,755	$521,000	+$521,000			$21.16	6